Barclays Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock Price

Posted by Geri Gentry on Oct 30th, 2026

Exelixis (NASDAQ:EXEL – Get Free Report) had its target price upped by investment analysts at Barclays from $49.00 to $54.00 in a report released on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would indicate a potential downside of 23.71% from the stock’s current price.

EXEL has been the subject of a number of other reports. Stifel Nicolaus lifted their price target on Exelixis from $47.00 to $51.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. UBS Group set a $55.00 target price on Exelixis in a research report on Monday, August 3rd. BMO Capital Markets restated a “market perform” rating and set a $60.00 target price on shares of Exelixis in a research note on Friday. Royal Bank Of Canada upped their price target on Exelixis from $45.00 to $51.00 and gave the company a “sector perform” rating in a report on Friday, October 9th. Finally, Zacks Research upgraded shares of Exelixis from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $52.29.

Read Our Latest Stock Analysis on EXEL

Exelixis Stock Up 6.9%

Exelixis stock traded up $4.58 during mid-day trading on Friday, reaching $70.78. 621,078 shares of the company’s stock were exchanged, compared to its average volume of 2,567,143. The company has a market cap of $17.54 billion, a P/E ratio of 22.21, a P/E/G ratio of 1.86 and a beta of 0.47. Exelixis has a twelve month low of $36.00 and a twelve month high of $71.87. The company has a fifty day moving average of $59.07 and a 200-day moving average of $50.79.

Exelixis (NASDAQ:EXEL – Get Free Report) last released its earnings results on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.05. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The firm had revenue of $658.70 million for the quarter, compared to analyst estimates of $646.51 million. During the same period in the prior year, the firm earned $0.78 earnings per share. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. Equities research analysts expect that Exelixis will post 3.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Exelixis news, Director Mary Beckerle sold 9,812 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the sale, the director directly owned 16,079 shares in the company, valued at approximately $862,799.14. The trade was a 37.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.60% of the company’s stock.

Institutional Trading of Exelixis

A number of institutional investors have recently added to or reduced their stakes in the stock. Private Client Services LLC lifted its position in shares of Exelixis by 0.7% during the 3rd quarter. Private Client Services LLC now owns 28,539 shares of the biotechnology company’s stock valued at $1,667,000 after acquiring an additional 209 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Exelixis by 0.5% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock worth $2,549,000 after acquiring an additional 281 shares during the period. Brindle & Bay Financial Advisors LLC grew its holdings in shares of Exelixis by 8.0% in the 3rd quarter. Brindle & Bay Financial Advisors LLC now owns 4,105 shares of the biotechnology company’s stock worth $240,000 after acquiring an additional 305 shares during the period. Soltis Investment Advisors LLC increased its stake in Exelixis by 7.0% in the 3rd quarter. Soltis Investment Advisors LLC now owns 4,868 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 320 shares in the last quarter. Finally, Mather Group LLC. increased its stake in Exelixis by 124.6% in the 3rd quarter. Mather Group LLC. now owns 757 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 420 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Trending Headlines about Exelixis

Here are the key news stories impacting Exelixis this week:

Positive Sentiment: Q3 earnings and revenue beat expectations. Exelixis reported revenue of $658.7 million, up 10.2% year over year, versus a consensus estimate of approximately $646.5 million. Non-GAAP EPS was $0.94, ahead of the $0.89 estimate and above $0.78 a year earlier. CABOMETYX remained the primary growth and profitability driver. Exelixis Surpasses Q3 Earnings and Revenue Estimates
Positive Sentiment: Pipeline catalysts are becoming more visible. Exelixis said the FDA has assigned a March 3, 2027 PDUFA date for zanzalintinib, while the company continues advancing “Wave 2” pivotal development plans. A regulatory decision and progress toward additional indications could expand the company’s growth beyond CABOMETYX. Exelixis Zanzalintinib PDUFA and Wave 2 Plans
Positive Sentiment: Profitability and cash generation remain strong. Third-quarter net income was reported at $218.1 million, operating cash flow reached $280.0 million, and operating profit increased year over year, supporting continued investment in clinical programs. Exelixis Third-Quarter Results and Corporate Updates
Neutral Sentiment: Investors still face a valuation and execution debate. EXEL’s strong rally has pushed the stock close to its 52-week high, while the median analyst price target cited in recent coverage is $52, below the current trading range. Future performance will depend on successful zanzalintinib development and regulatory execution.
Negative Sentiment: Recent insider activity has been one-sided. Several executives and directors reportedly sold shares during the past six months, with no insider purchases disclosed. These sales may weigh on sentiment, although they do not necessarily indicate deteriorating fundamentals. Exelixis Q3 Earnings and Insider Activity

Exelixis Company Profile

(Get Free Report)

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.